People
Governance grade: B- because Centene has a mostly strong, refreshed board structure, but 2025 guidance credibility, low insider ownership, and one economically relevant related-party independence issue keep trust conditional.
The People Running This Company
Sarah London | CEO stake
▲ 335,139 beneficial shares
Andrew Asher | CFO stake
▲ 314,580 beneficial shares
Frederick Eppinger | Chair stake
▲ 360,361 beneficial shares
Kenneth Burdick | Watch-list director stake
▲ 369,592 beneficial shares
The operating bench is credible for managed care, but not yet fully proven after the 2025 reset. The highest-trust feature is structural: an independent chair, finance-heavy audit talent, and no founder or promoter block; the lowest-trust feature is that management still has to prove the 2026 recovery is not just another forecast.
What They Get Paid
Pay is performance-heavy but still looks expensive after the year shareholders just absorbed. The CEO received $19.5M in Summary Compensation Table pay, mostly stock, while adjusted EPS fell to $2.08 and GAAP results included a $6.7B goodwill impairment; the mitigating facts are that the 2023-2025 performance RSUs vested at 0%, the 2025 annual cash incentive paid below target at 71.6%, and CEO compensation actually paid was only $4.6M because the stock fell.
Are They Aligned?
Skin-in-the-game score / 10
Directors and officers ownership
Institutional ownership
Open-market insider buys
The company is institution-controlled, not owner-operated. Sarah London bought 19,230 shares for about $490K in August 2025 after the stock dislocation, and Theodore Samuels bought 9,000 shares for about $249K in July 2025; the offset is Kenneth Burdick's roughly $2.6M open-market sale in December 2025, while most other reported disposals were tax withholding on vesting awards rather than discretionary selling.
Capital allocation is mixed. The 2024 $3.0B buyback looks poorly timed after the 2025 reset, while 2025 was more restrained at $400M of share repurchases and $189M of debt repurchases; the current posture is more credible if management keeps balance sheet repair ahead of optics-driven repurchases.
Board Quality
True board independence
Independent directors
▲ 9 total directors
Joined in last five years
Audit financial experts
The board can challenge management on finance, audit, technology, and public-company process. The weak spot is more specific: the Quality Committee is chaired by a non-independent director whose LifeStance relationship overlaps with a behavioral-health cost area that management itself identified as a major 2025 pressure point.
The Verdict
Governance Grade: B-
Skin-in-game score
True independence
2025 annual incentive payout
Centene earns a B-. Positives are a separated independent chair and CEO, strong audit and finance coverage, no controlling shareholder, 0% vesting on the 2023-2025 performance RSUs, and a real CEO open-market buy after the selloff. Concerns are low insider ownership, high reported pay after a severe guidance miss, pending securities-fraud allegations tied to the 2025 reset, prior PBM overcharge settlements, and the Burdick/LifeStance independence issue.
The most likely upgrade would be two clean years of guidance accuracy, margin recovery, and clearer disclosure around the LifeStance relationship. The most likely downgrade would be evidence that the 2025 guidance failure reflected weak controls or disclosure discipline rather than a bad underwriting cycle.